Teva Pharma (TEVA) Announces Launch of an Authorized Generic of Epiduo® Forte Gel (adapalene and benzoyl peroxide gel 0.3%/2.5%), in the U.S.
Get Alerts TEVA Hot Sheet
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 2.1%
Revenue Growth %: +0.8%
Join SI Premium – FREE
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of an authorized generic of Epiduo®1 Forte Gel (adapalene and benzoyl peroxide gel 0.3%/2.5%), in the United States.
Adapalene and benzoyl peroxide gel 0.3%/2.5% is a topical prescription medicine used to treat acne vulgaris.
“The launch of our first-to-market authorized generic version of Epiduo® Forte Gel in the U.S. provides patients with another important treatment option,” said Christine Baeder, SVP, Chief Operating Officer US Generics, Teva USA. “Continuing to advance and launch much-needed generic drugs is critical to ensuring access to quality medicines to everyone who needs them."
With nearly 550 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market, and holds the leading position in first-to-file opportunities, with approximately 100 pending first-to-files in the U.S. Currently, 1 in 11 generic prescriptions dispensed in the U.S. is filled with a Teva generic product.
Epiduo® Forte Gel had annual sales of $253 million in the U.S., according to IQVIA data, as of September 2021.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
- Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
- 22nd Century Group (XXII) Announces Resignation of Sullivan and Mish from Board
Create E-mail Alert Related Categories
Corporate NewsRelated Entities
Definitive Agreement, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!